COMMUNIQUÉS West-GlobeNewswire

Compass Pathways to announce first quarter financial results on May 8, 2024

03/05/2024 - 22:58

LONDON, May 03, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will [...]

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03/05/2024 - 22:45

BOSTON, May 03, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous [...]

Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03/05/2024 - 22:30

CAMBRIDGE, Mass., May 03, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs [...]

Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03/05/2024 - 22:30

NEW YORK and WALTHAM, Mass., May 03, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (“Dianthus”), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement [...]

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

03/05/2024 - 22:30

MALVERN, Pa., May 03, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life [...]

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

03/05/2024 - 22:30

SOUTH SAN FRANCISCO and SAN DIEGO, May 03, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic [...]

Fate Therapeutics Announces Presentation of FT522 Preclinical Data for Autoimmune Diseases in Late-breaking Abstract at ASGCT Annual Meeting

03/05/2024 - 22:30

Off-the-shelf, CD19-targeted CAR NK Cell Product Candidate Drives Rapid and Deep Depletion of SLE Donor CD19+ B cells ADR Technology Incorporated into FT522 Induces Functional Persistence and Eliminates Alloreactive [...]

Vision Sensing Acquisition Corp. Announces Payment of Fee to Extend Period to Consummate Initial Business Combination to June 3, 2024

03/05/2024 - 22:30

Filed by Vision Sensing Acquisition Corp. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Vision Sensing [...]

electroCore Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)

03/05/2024 - 22:05

ROCKAWAY, N.J., May 03, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that on May 1, 2024, Donald Melnikoff [...]

Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)

03/05/2024 - 22:05

FOSTER CITY, Calif., May 03, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product [...]

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

03/05/2024 - 22:05

DALLAS, May 03, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of severe [...]

Aileron Therapeutics Announces Closing of Underwritten Registered Direct Offering of up to Approximately $40 Million

03/05/2024 - 22:05

Includes initial funding of approximately $20 million, as well as the potential for additional proceeds of approximately $20 million from exercise of three-year warrants issued in offering AUSTIN, Texas, May 03, 2024 ( [...]

Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03/05/2024 - 22:01

BEDFORD, Mass., May 03, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that on May 1, 2024, Anika granted non- [...]

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03/05/2024 - 22:01

NAARDEN, the Netherlands and MIAMI, May 03, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, [...]

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

03/05/2024 - 22:01

CAMBRIDGE, Mass., May 03, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, effective as of May 1, 2024, the Compensation Committee of the Board [...]

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03/05/2024 - 22:00

WESTLAKE VILLAGE, Calif., May 03, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, [...]

Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03/05/2024 - 22:00

WALTHAM, Mass and DUBLIN, May 03, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company leveraging its core competencies in immune cell modulation and protein engineering [...]

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

03/05/2024 - 19:48

Bagsværd, Denmark, 3 May 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with [...]

Phase 2 data for ERLEADA® ▼(apalutamide) plus androgen deprivation therapy following radical prostatectomy in patients with high-risk localised prostate cancer shows 100 percent biochemical free recurrence rate more than two years post-surgery

03/05/2024 - 18:39

Study highlights opportunity for treatment intensification in this population since approximately 50 percent of patients with high-risk localised prostate cancer (HRLPC) experience disease recurrence within two years of [...]